Amgen faces patent infringement claims on big-selling osteoporosis drug Evenity
May 3, 2023
Source: drugdu
124
In developing its osteoporosis drug Evenity more than a decade ago, it is alleged in court documents that Amgen discussed forming a potential partnership with a small company from Kansas.
Those discussions never amounted to a deal. Now, 11 years later, the Kansas company is suing Amgen for patent infringement.
The suit, filed in U.S. District Court in Massachusetts, claims Amgen's Evenity infringes on three of patents owned by OssiFi-Mab, including one that was granted last month. The first patent was awarded in 2012, the same year that Amgen and the Kansas company talked of a potential collaboration, according to the suit.
The patents refer to the “discovery of methods of increasing bone density via administration of a sclerostin antagonist together with an antiresorptive,” the complaint says. Evenity works in part by decreasing bone resorption by inhibiting the action of sclerostin, which helps regulate bone metabolism.
Amgen declined to comment on the suit.
Reference:https://news.bloomberglaw.com/ip-law/amgen-sued-for-patent-royalties-on-evenity-osteoporosis-drug
By editor
Copyright©2024 Ddu. All rights reserved.
Read more on
- Over 5.7 billion! China’s dual antibody ADC goes global+1 November 21, 2024
- Is Jingtai Technology once again breaking through the “first AI pharmaceutical stock” halo and shedding? November 21, 2024
- Yangqi Medical Chip completes tens of millions of yuan in Pre-A round financing November 21, 2024
- Endovascular stent approved through priority green channel November 21, 2024
- Well-known products of foreign companies such as AZ, Eli Lilly, and Sanofi were disqualified November 21, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
